Assay for methylation in the gst-pi gene
AssigneeCommonwealth Scientific and Industrial Research Organisation
InventorsSusan J. Clark, Douglas S. Millar, Peter L. Molloy
Life of this patent
Estimating the term…
Abstract
A diagnostic or prognostic assay is disclosed for a disease of condition characterized by abnormal methylation of cytosine at side or sites within the glutathione-S-transferase (GST) Pi gene and/or its regulatory flanking sequences (e.g., prostate cancer and liver cancer). The assay comprises: (i) isolating DNA from said subject, and (ii) determining (e.g., by selective PCR amplification) the presence of abnormal methylation of cytosine at a site or sites within the GST-Pi gene and/or its regulatory flanking sequences.
Claims16
1-17. (canceled)
A method for diagnosing prostate cancer in a subject suspected of having prostate cancer, comprising:
- detecting, in a tissue or body fluid sample from said subject, the presence of an abnormally methylated cytosine in the glutathione S-transferase (GST) Pi gene, wherein the presence of said abnormally methylated cytosine is indicative of prostate cancer;
- and
- wherein said abnormally methylated cytosine is within a CpG site located within a region defined by and including nucleotides 495 to 1231 (CpG sites −56 to −1) of SEQ ID NO:
- 60.
Dependencies are inferred from the claim text.